Key Points
- Executive insider sale: EVP Roland Goette sold 2,438 Becton, Dickinson shares at an average price of $180.84, reducing his holdings by 14.1% to 14,856 shares.
- Quarterly performance: Becton, Dickinson reported adjusted EPS of $3.23, beating estimates by $0.09, while revenue rose 5.4% year over year to $4.98 billion. The company set fiscal 2026 EPS guidance at $12.62–$12.72.
- Market and shareholder outlook: Shares opened at $183.14, near the analyst consensus target of $185, with analysts’ overall rating at “Hold.” The company declared a quarterly dividend of $1.05, representing a 2.3% annualized yield.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Becton, Dickinson and Company Trading Up 1.0%
Shares of BDX stock opened at $183.14 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a fifty day moving average of $156.55 and a two-hundred day moving average of $161.69. The firm has a market capitalization of $50.46 billion, a PE ratio of 55.16, a price-to-earnings-growth ratio of 12.79 and a beta of 0.19.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the company earned $3.68 earnings per share. The company's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.
Becton, Dickinson and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio is currently 126.51%.
Analyst Upgrades and Downgrades
A number of analysts have commented on the stock. Bank of America dropped their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $175.00 to $180.00 and gave the company a "sector perform" rating in a research note on Friday, August 7th. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a report on Friday, August 7th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, Citigroup increased their price target on Becton, Dickinson and Company from $198.00 to $204.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $185.00.
View Our Latest Report on Becton, Dickinson and Company
Institutional Investors Weigh In On Becton, Dickinson and Company
A number of institutional investors and hedge funds have recently bought and sold shares of BDX. Auto Owners Insurance Co grew its stake in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the last quarter. BlackRock Inc. acquired a new stake in Becton, Dickinson and Company during the second quarter valued at approximately $3,721,533,000. Wellington Management Group LLP boosted its holdings in Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock worth $979,290,000 after buying an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Becton, Dickinson and Company by 13.0% during the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock worth $7,118,282,000 after buying an additional 4,223,149 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier's stock worth $769,397,000 after buying an additional 4,137,888 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.
Becton, Dickinson and Company Company Profile
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
